The data presented between September 30 and October 3 underscore the firm's focus on expanding treatment options for conditions including alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, and psoriasis.

Key updates include long-term efficacy data for the approved therapies SKYRIZI (risankizumab) and RINVOQ (upadacitinib), alongside initial findings for investigational agents lutikizumab and zumilokibart. According to Ryan DeMasi, vice president of global medical affairs, these findings aim to improve patient outcomes by advancing the scientific understanding of complex inflammatory pathways. The presentation includes three late-breaking studies that examine novel mechanisms of action, reinforcing the company’s ongoing investment in dermatology research.